Renal Cell Carcinoma News and Research

RSS

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.

Study Reveals Key Insights Into the Evolution of Tumor Microenvironment in Gastric Cancer

A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.

7 Jul 2023

Genes can be used to better predict the likelihood of kidney cancer recurrence

A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient's disease returning by looking at DNA mutations in their tumors.

24 Feb 2023

Researchers created ultrasound-guided microbubbles to enhance immunotherapy performance

The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.

1 Jun 2022

Researchers determine the novel medical target of angiogenesis for ccRCC patients

Research reported that the DMDRMR/miR-378a-5p/ DAB2IP axis enhances angiogenesis and sunitinib resistance, suggesting that it could be used for patients with ccRCC.

30 May 2022

Immune cell patterns can help predict kidney cancer patients' response to immunotherapy

Researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumors that can help predict if patients with kidney cancer will respond to immunotherapy.

29 Oct 2021

Targeted drug shows promise against brain metastases from kidney cancer

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

22 Oct 2021

New technology efficiently delivers immune checkpoint inhibitors for treating brain tumors

Multi-institutional researchers have succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificity in treating orthotopically transplanted mice with glioblastoma (GBM). The research was published in Nature Biomedical Engineering.

12 Oct 2021

Natural killer cells target breast cancer using the body’s immune system

In a recent study, researchers investigated how natural killer cells target breast cancer using the body's own immune system.

18 Jun 2021

Immunotherapy following kidney cancer surgery prolonged disease-free survival rates

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.

4 Jun 2021

Genetic changes in tumors could help predict patient's response to immunotherapy drugs

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients.

28 Jan 2021

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

24 Sep 2020

In-depth study of kidney tumors reveals novel markers of response to immunotherapy

Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.

9 Sep 2020

Greater gut microbial diversity in kidney cancer patients linked to better treatment outcomes

Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.

20 Aug 2020

Total-body dynamic PET scans can produce high-quality images of metastatic cancer

Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.

14 Jul 2020